An observational study in Ischemic Heart Disease, Acute Coronary Syndrome and Acute Myocardial Infarction, sponsored by InspireMD. Completed at 2 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-06.
Sponsored by InspireMD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Acute Coronary Syndrome with a site in Israel — none open to participants now, 1 under way, none of them phase 3. Acute Coronary Syndrome · Israel.
Among the 39 studies in Acute Coronary Syndrome with a site in Israel, this one is the 6th largest by enrollment of the 11 observational ones that give a count, is one of 5 that started in 2009, is one of 11 observational ones, and was the 13th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →None of the 39 studies in Acute Coronary Syndrome with a site in Israel is open now. The open studies under Acute Coronary Syndrome, anywhere →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is below the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Median enrollment 3,497 across the 28 interventional studies, 86 across the 11 observational. Of the 28 that completed or were terminated, 14 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 39 have an industry lead sponsor. The 10 most frequent:
InspireMD is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
InspireMD has 1 study filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Acute Coronary Syndrome with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07776184Tel Aviv Medical CenterMulti-Component Delirium Prevention Bundle in Older Cardiac Intensive Care Unit Patients | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Acute Coronary Syndrome with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
the objective of the Israeli MGurad Registry is to evaluate the 'Real World' Clinical Performance of the InspireMD MGuard Coronary Stent System
A Prospective, Observational, Multicenter Registry The primary objective of this registry is to document the safety and overall clinical performance of the MGuard Coronary Stent System in a "real world" patient population requiring stent implantation.
The secondary objective is to assess the event rate in patient subgroups with specific clinical indications and/or vessel and/or lesion characteristics.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
This study's enrollment of 86 is below the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Browse Acute Coronary Syndrome studies →InspireMD is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Compared within Acute Coronary Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Ischemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients with an indication for coronary stent implantation according to the Israeli regulatory approval of the MGuard Coronary Stent System. All patients who receive one or more MGuard Coronary Stent System in one or more target lesions should be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
eligible patients implanted with minimum one MGuard stent
Device: MGuard Coronary Stent system
MGuard Coronary Stent system implanted within a PCI
Also known as: MGuard
Major Cardiac Adverse Events rate (MACE)
Time frame: 1 month
Major Cardiac Adverse Events rate (MACE)
Time frame: 6 months
Lesion success rate
Time frame: 1 day
Bleeding complications
Time frame: 6 months
Stent thrombosis rate
Time frame: 6 months
Any death
Time frame: 6 months
The record gives a start of Jul 2009, a primary completion of Jun 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InspireMD